Navigation Links
NuVasive Completes Acquisition of Osteocel Biologics Business
Date:7/24/2008

SAN DIEGO, July 24, 2008 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it has completed the previously announced acquisition of the Osteocel biologics business from Osiris Therapeutics, Inc. (Nasdaq: OSIR) for $35 million in cash, plus additional milestone-based contingent payments not to exceed $50 million in either cash or stock, at NuVasive's election. The core of the Osteocel business is a proprietary adult stem cell bone graft product.

Osteocel is the only viable bone matrix product on the market that provides the three beneficial properties similar to autograft: osteoconduction (provides a scaffold for bone growth), osteoinduction (bone formation stimulation) and osteogenesis (bone production). Osteocel allows surgeons to offer the benefits of these properties to patients without the discomfort and potential complications of autograft harvesting, in addition to eliminating the time spent on a secondary surgical procedure. Osteocel is produced for use in spine applications through a proprietary processing method that preserves the native stem cell population that resides in marrow rich bone.

Strategic benefits of the transaction to NuVasive:

-- Provides comprehensive stem cell biologic platform with benefits similar to autograft;

-- Proprietary production process with significant supply capacity;

-- Strengthens biologics platform for
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
2. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
3. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
4. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
7. NuVasive to Host Investor Reception on September 11, 2007
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
10. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
11. Accuri Cytometers Completes $13 Million Series C Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , SARASOTA, Fla., Dec. 1 E..., Osprey Biotechnics Inc. of Sarasota has appointe...ributor. ,, Lake is located near Birmingham, E...al bacteria which serve the agricultural, waste wa...red to be hungry and to open drain fields, and cle...
(Date:12/1/2009)... , SAN FRANCISCO, Dec. 1 The ...almost half the value it lost in October. The Sele... excellent month for the general markets with the ...n value. The gains held firm in the final two trad...ut sluggish Thanksgiving holiday shopping and Duba...
(Date:12/1/2009)... EpiVax, Inc. today announced...X: RO, ROG; OTCQX: RHHBY) aimed at evaluating EpiV... could potentially reduce detrimental immune respo...EpiVax collaboration, the EpiVax Tregitope technol...ogenicity of protein therapeutics. , ...
(Date:12/1/2009)... , CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCa... ) today announced that the U.S. Patent and Tradem...itled "Cyclic Natriuretic Peptide Constructs." Th...clic compounds that bind to natriuretic peptide re... heart failure drug candidate. ,, "Our natriure...
Breaking Biology Technology:Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
...in 2005 added up to more than $19 million across 4...ort released on Wednesday. , ,The investor tax cre...or the first time, start to officially track the v...it,s not entirely complete, it,s the first good pi...al sector," said David Ward, president of NorthSta...
Johnson Controls buys stake in health-care tech integration firm
...is the founder of Milwaukee investment company Lub...isconsin, is giving $10 million to the business sc...ty has received and will fund business professorsh... also said he would help the university raise anot...ry to persuade the state government and UW System ...
Other Biology Technology:State tracks more angel investment, at least $19M last year 2
(Date:12/1/2009)...ng, ants have two different feeding strategies. A..." meaning that they are generalist predators feedi...emains. Some, however, are "herbivorous". This i...e bulk of their diets consist of plant-derived mat...duced by plants to attract ants, called extra-flor...
(Date:12/1/2009)...09: OptiNose is pleased to announce the publicatio...stigating the efficacy and tolerability of its nov... treatment of chronic rhinosinusitis with nasal po...nternational and European Rhinologic Societies. ,...hronic disease that can significantly reduce a pat...
(Date:12/1/2009)...n Alzheimer,s disease, nerve cell degeneration pla...options may possibly be derived from steering the ...ngs have been published in the current issue of th...ly a few years ago, neurogenesis the process of n...ible in the adult brain. The textbooks asserted th...
Breaking Biology News(10 mins):Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2New source discovered for the generation of nerve cells in the brain 2Video 3A Home Spun or Hard Fact 3F 56709 1Video 3A Home Spun or Hard Fact 3F 56709 2Video 3A Home Spun or Hard Fact 3F 56709 3Video 3A Home Spun or Hard Fact 3F 56709 4QIAGENs New Product Line QIAsafe 28R 29 DNA Blood has Been Co Developed With Biomatrica and is Based on Biomatricas SampleMatrix 28R 29 Technology 13958 1QIAGENs New Product Line QIAsafe 28R 29 DNA Blood has Been Co Developed With Biomatrica and is Based on Biomatricas SampleMatrix 28R 29 Technology 13958 2QIAGENs New Product Line QIAsafe 28R 29 DNA Blood has Been Co Developed With Biomatrica and is Based on Biomatricas SampleMatrix 28R 29 Technology 13958 3QIAGENs New Product Line QIAsafe 28R 29 DNA Blood has Been Co Developed With Biomatrica and is Based on Biomatricas SampleMatrix 28R 29 Technology 13958 4National Alliance for Hispanic Health Applauds President Obamas Efforts to Achieve Meaningful Health Care Reform in 2009 56702 1National Alliance for Hispanic Health Applauds President Obamas Efforts to Achieve Meaningful Health Care Reform in 2009 56702 2
...ct that millions of Americans are believed to have...e method exists to treat many of these people. Tha...ell loss are varied and complex, ranging from chro... apparent reason at all. Some seven percent of Ame...their ability to enjoy the fragrance of flowers, f...
... 1911, the influential geneticist Charles Davenpor...vancing his ideas of how genetics would improve so...xtbook and a foundation for the widespread eugenic...enic ideals of the early part of the 20th century ... by Davenport are still being debated nearly 100 y...
...atrics, edited and sponsored by the National Insti...icians will have access in one place to the review...behavioral, and environmental changes during child...aintenance, and acceleration of illegal use of alc...ection of where science is in our understanding of...
Other Biology News:For some who have lost their sense of smell, a once popular asthma drug could help 2For some who have lost their sense of smell, a once popular asthma drug could help 3Reflecting on the social implications of human genetics research -- past, present and future 2Pediatricians alerted to the developmental nature of underage drinking in special journal supplement 2Pediatricians alerted to the developmental nature of underage drinking in special journal supplement 3Pediatricians alerted to the developmental nature of underage drinking in special journal supplement 4
... microscope is described by end-users to be "a del...f light microscopy and electronic imaging. With it...t require much space and can easily be accommodate... Motic's own revolutionary Colour Corrected Infini...
...Fujifilm Life Science BAS-5000 is the highest reso...he top member of Fujifilm's family of BAS scanners...angeable resolutions (25/50m) for versatility in t...compromising experiment speedeven the highest reso...
Anti-human CD41 Tetramer, 200 uL from StemCell Technologies, Inc.
...per software products bring you ease of use and ra...ts for data management and quality control. ... CLARA® is the stan...gro Modules allowing for the simple interface with...
Biology Products: